Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
320 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04358276 | Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study | active not recruiting | N/A | 840 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 |
| clinicaltrials |
| NCT06539468 | Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients | active not recruiting | N/A | 81 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04929028 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01787409 | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | active not recruiting | N/A | 565 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04305145 | Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | active not recruiting | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | active not recruiting | Phase 1 | 43 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04960618 | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | active not recruiting | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07624981 | Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions(DIAGNO-KA) | active not recruiting | — | 140 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03944941 | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer | active not recruiting | Phase 2 | 60 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04315701 | A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer | active not recruiting | Phase 2 | 35 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06608511 | Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | active not recruiting | — | 20 | University of Wisconsin, MadisonOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07422805 | Circulating Tumor DNA in Melanoma Patients(ctDNA) | active not recruiting | Phase 1 / Phase 2 | 176 | Institute of Oncology LjubljanaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT02965716 | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | active not recruiting | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | May 20, 2026 | clinicaltrials |
| NCT03491176 | Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer | active not recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05574101 | A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | active not recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | May 12, 2026 | clinicaltrials |
| NCT04349436 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies(ARTACUS) | active not recruiting | Phase 1 / Phase 2 | 69 | Replimune, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05507541 | TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01955460 | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03361436 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | active not recruiting | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04869137 | Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma | active not recruiting | Phase 2 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03240211 | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | active not recruiting | Phase 1 | 37 | University of VirginiaOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03737734 | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT) | active not recruiting | N/A | 30 | Alpha Tau Medical LTD.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06327971 | Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology | active not recruiting | — | 300 | Queen Mary University of LondonOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03969004 | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 3 | 415 | Regeneron PharmaceuticalsINDUSTRY | 16 | Mar 27, 2026 | clinicaltrials |
| NCT05724875 | FLASH Radiotherapy for Skin Cancer(LANCE) | active not recruiting | N/A | 60 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06008977 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy(EX-BOOST) | active not recruiting | N/A | 12 | AdventHealth Translational Research InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04744935 | Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma | active not recruiting | N/A | 40 | Christopher ZacharyOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03071406 | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | active not recruiting | Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04020809 | Neoadjuvant Atezolizumab in Cutaneous Melanoma | active not recruiting | Phase 1 | 20 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | active not recruiting | Phase 1 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07415291 | CNN-Based AI Versus Physicians for Solitary Skin Lesion Diagnosis | active not recruiting | — | 17,625 | Istanbul Training and Research HospitalOTHER_GOV | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | active not recruiting | Phase 2 | 50 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | active not recruiting | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07376317 | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)(OTIMAS) | active not recruiting | Phase 2 | 29 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). | active not recruiting | Phase 3 | 187 | Biofrontera Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT00588315 | In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin | active not recruiting | — | 1,889 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | active not recruiting | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 25, 2026source: clinicaltrials